Please assess the completion status of the following clinical trial:

Trial Title: MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with malignant melanoma~* Measurable unresectable Stage III or IV melanoma~* HLA-A\*0201 positive~* Previous treatment with \& failure/relapse/inability to tolerate IL-2, dacarbazine and/or temozolomide~* At least 4 weeks since prior treatment~* Negative pregnancy~* Life expectancy greater than 4 months~* Eastern Cooperative Oncology Group (ECOG) performance of 0 or 1~* Required lab values~* Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) negative~Exclusion Criteria:~* Prior malignancies which the patient has not been disease free for over 5 years, except treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or any other cancer~* Ocular melanoma~* Active, untreated central nervous system (CNS) metastasis~* Prior treatment with MDX-010 (anti-CTLA4) antibody~* Prior treatment with any cancer therapeutic vaccine~* Active autoimmune disease or history of autoimmune disease~* Pregnancy or nursing~* Hypersensitivity to Incomplete Freund's Adjuvant (IFA) (Montanide ISA-51)~* Underlying medical conditions deemed hazardous if treated with study drug~* Concomitant therapy with anti-melanoma drugs, chemotherapies, other investigational therapies, chronic use of systemic corticosteroids~* Unable to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Melanoma Peptide Vaccine (MDX-1379) (gp100) + Placebo
- 2 (Type: EXPERIMENTAL): MDX-010 (ipilimumab) + MDX-1379 (gp100) (Melanoma Peptide Vaccine)
- 3 (Type: ACTIVE_COMPARATOR): MDX-010 (ipilimumab) + Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).